Bristol-Myers Squibb Company (BMY)
NYSE: BMY · Real-Time Price · USD
55.83
+0.04 (0.07%)
At close: Feb 21, 2025, 4:00 PM
56.00
+0.17 (0.30%)
After-hours: Feb 21, 2025, 7:53 PM EST
BMY Revenue
In the year 2024, Bristol-Myers Squibb Company had annual revenue of $48.30B with 7.32% growth. Bristol-Myers Squibb Company had revenue of $12.34B in the quarter ending December 31, 2024, with 7.54% growth.
Revenue (ttm)
$48.30B
Revenue Growth
+7.32%
P/S Ratio
2.34
Revenue / Employee
$1,416,422
Employees
34,100
Market Cap
113.30B
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2024 | 48.30B | 3.29B | 7.32% |
| Dec 31, 2023 | 45.01B | -1.15B | -2.50% |
| Dec 31, 2022 | 46.16B | -226.00M | -0.49% |
| Dec 31, 2021 | 46.39B | 3.87B | 9.09% |
| Dec 31, 2020 | 42.52B | 16.37B | 62.62% |
| Dec 31, 2019 | Pro | Pro | Pro |
| Dec 31, 2018 | Pro | Pro | Pro |
| Dec 31, 2017 | Pro | Pro | Pro |
| Dec 31, 2016 | Pro | Pro | Pro |
| Dec 31, 2015 | Pro | Pro | Pro |
Sources: Historical revenue is based on company filings submitted to the U.S. Securities and Exchange Commission (SEC). The most recent revenue numbers may be taken from company press releases.
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| UnitedHealth Group | 400.28B |
| Johnson & Johnson | 88.82B |
| Merck & Co. | 64.17B |
| AbbVie | 56.33B |
| AstraZeneca | 54.07B |
| Novartis AG | 51.72B |
| Eli Lilly and Company | 45.04B |
| Thermo Fisher Scientific | 42.88B |
BMY News
- 1 day ago - Bristol-Myers Squibb Stock: A Strong Buy Amid Oncology Success - Seeking Alpha
- 3 days ago - BioArctic's global license agreement with Bristol Myers Squibb for PyroGlutamate-amyloid-beta antibody program effective after antitrust clearance and closing - PRNewsWire
- 4 days ago - Wall Street's Most Accurate Analysts Weigh In On 3 Health Care Stocks With Over 4% Dividend Yields - Benzinga
- 4 days ago - Bristol Myers Squibb Announces Opdivo® Plus Chemotherapy as the First and Only Neoadjuvant-Only Immuno-Oncology Therapy to Demonstrate Statistically Significant and Clinically Meaningful Overall Survival in Resectable Non-Small Cell Lung Cancer - Business Wire
- 7 days ago - Buy 5 'Safer' Dividend Dogs Of 23 February Barron's Better Bets Than T-Bills - Seeking Alpha
- 7 days ago - New Five-Year Sotyktu (deucravacitinib) Data Show Consistent Safety and Durable Response Rates in Moderate-to-Severe Plaque Psoriasis - Business Wire
- 9 days ago - Bristol Myers Squibb Provides Update on Phase 3 RELATIVITY-098 Trial - Business Wire
- 12 days ago - What's Going On With Bristol Myers Squibb Stock On Monday? - Benzinga